Study identifier:D7260C00001
ClinicalTrials.gov identifier:NCT06579092
EudraCT identifier:N/A
CTIS identifier:2024-513691-18-00
A Phase IIb Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of AZD5004 in Participants Living with Obesity or Overweight with Comorbidity
Obesity or Overweight
Phase 2
No
AZD5004, Placebo
All
285
Interventional
18 Years - n/a
Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment
Verified 01 Aug 2024 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: Arm 1 Active IMP | Drug: AZD5004 AZD5004 film-coated tablet once daily during 36 weeks Other Name: Active IMP |
Experimental: Arm 2 Active IMP | Drug: AZD5004 AZD5004 film-coated tablet once daily during 36 weeks Other Name: Active IMP |
Experimental: Arm 3 Active IMP | Drug: AZD5004 AZD5004 film-coated tablet once daily during 36 weeks Other Name: Active IMP |
Experimental: Arm 4 Active IMP | Drug: AZD5004 AZD5004 film-coated tablet once daily during 36 weeks Other Name: Active IMP |
Experimental: Arm 5 Active IMP | Drug: AZD5004 AZD5004 film-coated tablet once daily during 36 weeks Other Name: Active IMP |
Placebo Comparator: Arm 6 Matching placebo for each of the 5 active arms | Drug: Placebo Placebo matching AZD5004 film-coated tablet once daily during 36 weeks Other Name: Placebo |